Literature DB >> 27424071

Executive Summary of the Guidelines for the Use of interferon-gamma Release Assays in the Diagnosis of Tuberculosis Infection.

Miguel Santin1, José-María García-García2, David Rigau3, Neus Altet4, Luis Anibarro5, Irma Casas6, Nuria Díez7, Mercedes García-Gasalla8, Xavier Martínez-Lacasa9, Antón Penas10, Elvira Pérez-Escolano11, Francisca Sánchez12, José Domínguez13.   

Abstract

Interferon-gamma release assays are widely used for the diagnosis of tuberculosis infection in Spain. However, there is no consensus on their application in specific clinical scenarios. To develop a guide-line for their use, a panel of experts comprising specialists in infectious diseases, respiratory diseases, microbiology, pediatrics and preventive medicine, together with a methodologist, conducted a systematic literature search, summarized the findings, rated the quality of the evidence, and formulated recommendations following the Grading of Recommendations of Assessment Development and Evaluations methodology. This document provides evidence-based guidance on the use of interferon-gamma release assays for the diagnosis of tuberculosis infection in patients at risk of tuberculosis or suspected of having active disease. The guidelines will be applicable to specialist and primary care, and public health.
Copyright © 2016 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Guideline; Guía de uso en la práctica clínica; Infección tuberculosa latente; Interferon-gamma release assays; Latent tuberculosis infection; Prevención; Prevention; Pruebas de liberación de interferón-gamma; Tuberculosis

Mesh:

Year:  2016        PMID: 27424071     DOI: 10.1016/j.arbres.2016.02.020

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  1 in total

1.  [Concordance between the test of the tuberculin and Interferon Gamma Release Assay-IGRA in patients with immune-mediated inflammatory diseases].

Authors:  I Pérez Catalán; C Roig Martí; M Gil Fortuño; P Torrent Ramos; P Albiol Viñals; M Carballido Fernández; R M Larrea; C Ortín Martín; J Usó Blasco; J M Ramos Rincón
Journal:  Rev Esp Quimioter       Date:  2019-09-16       Impact factor: 1.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.